Autologous tumor neoantigens (polyclonal, patient-specific) drugs for Non-Small Cell Lung Cancer

2 tracked Autologous tumor neoantigens (polyclonal, patient-specific) drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the Autologous tumor neoantigens (polyclonal, patient-specific) page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.

1 Phase 21 Phase 1

The roster

← all Autologous tumor neoantigens (polyclonal, patient-specific) drugs